Repression of Osteoblast Maturation by ERRα Accounts for Bone Loss Induced by Estrogen Deficiency

PLoS ONE

Volumn 8, Issue 1, 2013, Pages

  Gallet, Marlène ^a   Saïdi, Soraya ^b   Haÿ, Eric ^b   Photsavang, Johann ^c   Marty, Caroline ^b   Sailland, Juliette ^a   Carnesecchi, Julie ^a   Tribollet, Violaine ^a   Barenton, Bruno ^a   Forcet, Christelle ^a   Birling, Marie Christine ^d   Sorg, Tania ^d   Chassande, Olivier ^c   Cohen Solal, Martine ^b   Vanacker, Jean Marc ^a  

^a UNIVERSITÉ DE LYON   (France)

^b HÔPITAL LARIBOISIÈRE   (France)

^c INSERM   (France)

^d INSTITUT CLINIQUE DE LA SOURIS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE AGE; BONE ATROPHY; BONE DENSITY; CELL DIFFERENTIATION; CELL LINEAGE; CELL MATURATION; CONTROLLED STUDY; FEMALE; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; OSTEOBLAST; PROTEIN FUNCTION;

ANIMALS; CELL LINEAGE; ESTROGEN RECEPTOR ALPHA; ESTROGENS; MALE; MICE; MICE, KNOCKOUT; MICE, TRANSGENIC; OSTEOBLASTS; OSTEOPOROSIS; RABBITS;

ANIMALIA; MUS;

EID: 84872865852     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0054837     Document Type: Article

References (36)

1. Manolagas SC, Parfitt AM, (2010) What old means to bone. Trends Endocrinol Metab 21: 369-74.
2. Manolagas SC, (2010) From estrogen-centric to ageing and oxidative stress: a revised perspective of the pathogenesis of osteoporosis. Endocrine Rev 31: 266-300.
3. Li CI, Malone KE, Porter PL, Weiss NS, Tang MT, et al. (2003) Relationship between long durations and different regimens of hormone therapy and risk of breast cancer. JAMA. 289: 3254-63.
4. Collins JA, Blake JM, Crosignani PG, (2005) Breast cancer risk with postmenopausal hormonal treatment. 2005 Hum Reprod Update. 11: 545-60.
5. Horwitz KB, (2008) The Year in Basic Science: update of estrogen plus progestin therapy for menopausal hormone replacement implicating stem cells in the increased breast cancer risk. Mol Endocrinol. 22: 2743-50.
6. Marie PJ, Kassem M, (2011) Ostoblasts in osteoporosis: past, emerging, and future anabolic targets. Eur J Endrocinol 165: 1-10.
7. Khosla S, Westendorf JJ, Oursler MJ, (2008) Building bone to reverse osteoporosis and repair fractures. J Clin Invest 118: 421-8.
8. Komori T, (2010) Regulation of bone development and extracellular matrix protein genes by RUNX2 Cell Tissue Res. 339: 189-195.
9. Tremblay AM, Giguère V, (2007) The NR3B subgroup: an ovERRview. Nucl Recept Signal 5: e009.
10. Willy PJ, Murray IR, Qian J, Busch BB, Stevens WC Jr, et al. (2004) Regulation of PPARgamma coactivator 1alpha (PGC-1alpha) signaling by an estrogen-related receptor alpha (ERRalpha) ligand. Proc Natl Acad Sci U S A. 101: 8912-7.
11. Lanvin O, Bianco S, Kersual N, Chalbos D, Vanacker JM, (2007) Potentiation of ICI182,780 (Fulvestrant)-induced estrogen receptor-alpha degradation by the estrogen receptor-related receptor-alpha inverse agonist XCT790. J Biol Chem. 282: 28328-34.
12. Chisamore MJ, Cunningham ME, Flores O, Wilkinson HA, Chen JD, (2009) Characterization of a novel small molecule subtype specific estrogen-related receptor alpha antagonist in MCF-7 breast cancer cells. PLoS One. 4: e5624.
13. Duellman SJ, Calaoagan JM, Sato BG, Fine R, Klebansky B, et al. (2010) A novel steroidal inhibitor of estrogen-related receptor alpha (ERR alpha) Biochem Pharmacol. 80: 819-26.
14. Ariazi EA, Jordan VC, (2006) Estrogen-related receptors as emerging targets in cancer and metabolic disorders. Curr Top Med Chem. 6: 203-15.
15. Stein RA, Gaillard S, McDonnell DP, (2009) Estrogen-related receptor alpha induces the expression of vascular endothelial growth factor in breast cancer cells. J Steroid Biochem Mol Biol. 114: 106-12.
16. Bianco S, Lanvin O, Tribollet V, Macari C, North S, et al. (2009) Modulating estrogen receptor-related receptor-alpha activity inhibits cell proliferation. J Biol Chem. 284: 23286-92.
17. Fradet A, Sorel H, Bouazza L, Goehrig D, Dépalle B, et al. (2011) Dual function of ERRα in breast cancer and bone metastasis formation: implication of VEGF and osteoprotegerin. Cancer Res. 71: 5728-38.
18. Bianco S, Sailland J, Vanacker JM, (2012) ERRs and cancers: Effects on metabolism and on proliferation and migration capacities J Steroid Biochem Mol Biol. 130: 180-5.
19. Chang CY, Kazmin D, Jasper JS, Kunder R, Zuercher WJ, et al. (2011) The metabolic regulator ERRα, a downstream target of HER2/IGF-1R, as a therapeutic target in breast cancer. Cancer Cell. 20: 500-10.
20. Giguère V, (2008) Transcriptional control of energy homeostasis by the estrogen-related receptors. Endocr Rev 29: 677-96.
21. Villena JA, Kralli A, (2008) ERRalpha: a metabolic function for the oldest orphan Trends Endocrinol Metab. 19: 269-76.
22. Ijichi N, Ikeda K, Horie-Inoue K, Yagi K, Okazaki Y, et al. (2007) Estrogen-related receptor alpha modulates the expression of adipogenesis-related genes during adipocyte differentiation Biochem Biophys Res Commun. 358: 813-8.
23. Delhon I, Gutzwiller S, Morvan F, Rangwala S, Wyder L, et al. (2009) Absence of estrogen receptor-related-alpha increases osteoblastic differentiation and cancellous bone mineral density. Endocrinology 150: 4463-72.
24. Teyssier C, Gallet M, Rabier B, Monfoulet L, Dine J, et al. (2009) Absence of ERRalpha in female mice confers resistance to bone loss induced by age or estrogen-deficiency. PLoS One 4: e7942.
25. Auld KL, Berasi SP, Liu Y, Cain M, Zhang Y, et al. (2012) Estrogen-related receptor α regulates osteoblast differentiation via Wnt/β-catenin signaling. J Mol Endocrinol 48: 177-191.
26. Jeong BC, Lee YS, Park YY, Bae IH, Kim DK, et al. (2009) The orphan nuclear receptor estrogen receptor-related receptor gamma negatively regulates BMP2-induced osteoblast differentiation and bone formation. J Biol Chem. 284: 14211-8.
27. Gallet M, Vanacker JM, (2010) ERR receptors as potential targets in osteoporosis. Trends Endocrinol Metab 21: 637-41.
28. Dacquin R, Starbuck M, Schinke T, Karsenty G, (2002) Mouse alpha1(I)-collagen promoter is the best known promoter to drive efficient Cre recombinase expression in osteoblast. Dev Dyn 224: 245-51.
29. Bonnelye E, Merdad L, Kung V, Aubin JE, (2001) The orphan nuclear estrogen receptor-related receptor alpha (ERRalpha) is expressed throughout osteoblast differentiation and regulates bone formation in vitro. J Cell Biol. 153: 971-84.
30. Vanacker JM, Delmarre C, Guo X, Laudet V, (1998) Activation of the osteopontin promoter by the orphan nuclear receptor estrogen receptor related alpha. Cell Growth Differ 9: 1007-14.
31. Ducy P, Zhang R, Geoffroy V, Rydall AL, Karsenty G, (1997) Osf2/Cbfa1, a transcriptional regulator of osteoblast differentiation. Cell 8: 747-754.
32. Vico L, Vanacker JM, (2010) Sex hormones and their receptors in bone homeostasis: insights from genetically modified mouse models. Osteopos Int 21: 365-72.
33. Wei W, Wang X, Yang M, Smith LC, Dechow PC, et al. (2010) PGC1β mediates PPARγ activation of osteoclastogenesis and rosiglitazone-induced bone loss. Cell Metab 11: 503-16.
34. Yoshitake H, Rittling SR, Denhardt DT, Noda M, (1999) Osteopontin-deficient mice are resistant to ovariectomy-induced bone resorption. Proc Natl Acad Sci U S A. 96: 8156-60.
35. Macari C, Teyssier C, Tribollet V, Mouzat K, Forcet C, et al. (2010) Estrogens repress PGC1-α expression in the uterus. Mol Cell Endocrinol. 330: 33-40.
36. Vanacker JM, Bonnelye E, Chopin-Delannoy S, Delmarre C, Cavaillès V, et al. (1999) Transcriptional activities of the orphan nuclear receptor ERRα. Mol Endocrinol 13: 764-773.